IL22 and psoriasis: A recent clinical trial has demonstrated that oral delivery of Meriva (a lecithin based delivery system of curcumin) was effective as an adjuvant therapy for the treatment of psoriasis and was shown to significantly reduce serum levels of IL-22 and PASI scores in patients with mild-moderate disease32.